Hybrigenics has released an update on the development of it's vitamin D receptor agonist inecalcitol. The update includes clinical trial results from a Phase II study on treatment of chronic lymphocytic leukaemia (CLL). The study was conducted in 24 patients, 21 of which were evaluable, demonstrating 52% of patients seeing a decrease or stabilisation of blood lymphocyte counts following treatment of between four and 23 months.

Seven patients dropped out of the study and two patients experienced adverse events. Hybrigenics has also noted that it has received approval to commence a Phase II clinical trial of inecalcitol in CML patients treated with Novartis' Gleevec (imatinib). Hybrigenics aims to enroll the first patients into this study by the end of 2012.